- Home
- NNDM vs RIGL Comparison
NNDM vs RIGL Comparison
Compare NNDM & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNDM
- RIGL
- Stock Information
- Founded
- NNDM 2012
- RIGL 1996
- Country
- NNDM United States
- RIGL United States
- Employees
- NNDM N/A
- RIGL N/A
- Industry
- NNDM Electrical Products
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- NNDM Technology
- RIGL Health Care
- Exchange
- NNDM Nasdaq
- RIGL Nasdaq
- Market Cap
- NNDM 334.6M
- RIGL 335.5M
- IPO Year
- NNDM N/A
- RIGL 2000
- Fundamental
- Price
- NNDM $1.33
- RIGL $31.70
- Analyst Decision
- NNDM
- RIGL Buy
- Analyst Count
- NNDM 0
- RIGL 5
- Target Price
- NNDM N/A
- RIGL $38.20
- AVG Volume (30 Days)
- NNDM 2.7M
- RIGL 420.1K
- Earning Date
- NNDM 08-19-2025
- RIGL 08-05-2025
- Dividend Yield
- NNDM N/A
- RIGL N/A
- EPS Growth
- NNDM N/A
- RIGL N/A
- EPS
- NNDM N/A
- RIGL 5.43
- Revenue
- NNDM $58,812,000.00
- RIGL $267,921,000.00
- Revenue This Year
- NNDM N/A
- RIGL $14.41
- Revenue Next Year
- NNDM N/A
- RIGL $15.97
- P/E Ratio
- NNDM N/A
- RIGL $5.83
- Revenue Growth
- NNDM 7.49
- RIGL 105.62
- 52 Week Low
- NNDM $1.33
- RIGL $9.92
- 52 Week High
- NNDM $2.74
- RIGL $32.40
- Technical
- Relative Strength Index (RSI)
- NNDM 31.66
- RIGL 88.33
- Support Level
- NNDM $1.37
- RIGL $20.28
- Resistance Level
- NNDM $1.42
- RIGL $21.41
- Average True Range (ATR)
- NNDM 0.06
- RIGL 1.54
- MACD
- NNDM -0.01
- RIGL 1.25
- Stochastic Oscillator
- NNDM 4.55
- RIGL 94.62
About NNDM Nano Dimension Ltd.
Nano Dimension Ltd provide industrial manufacturing solutions for design-to-manufacturing of electronics and mechanical parts. These solutions are based on a combination of hardware, software, and materials science technologies. The solutions include industrial machinery, such as those for additive manufacturing, surface-mount technology, industrial inkjet printing, along with software for design, simulation, and manufacturing management, as well as materials or consumables that are used by the machinery. These solutions are used by industrial customers in aerospace & defense, automotive, electronics, medical, research and academia, along with government organizations.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.